MDT - Medtronic plc

NYSE - NYSE Delayed Price. Currency in USD
119.03
+0.17 (+0.14%)
At close: 4:01PM EST

118.96 -0.07 (-0.06%)
Pre-Market: 8:20AM EST

Stock chart is not supported by your current browser
Previous Close118.86
Open118.95
Bid118.78 x 800
Ask119.33 x 1100
Day's Range118.56 - 119.84
52 Week Range82.77 - 119.84
Volume4,906,103
Avg. Volume4,118,188
Market Cap159.545B
Beta (5Y Monthly)0.60
PE Ratio (TTM)33.81
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.16 (1.81%)
Ex-Dividend DateDec 24, 2019
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Medtronic Recognized with Prestigious Catalyst Award

    DUBLIN, Jan. 16, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT), the global leader in medical technology, has been named one of three recipients of the 2020 Catalyst Award, which recognizes corporations and the groundbreaking initiatives they’ve created to foster an inclusive workplace where women can advance. Medtronic is being recognized for the Medtronic Women’s Network (MWN) and Women in Science and Engineering (WISE) initiatives, key drivers in the company’s overall Inclusion and Diversity strategy. One of five internally established diversity networks within the company, the MWN was refocused by Medtronic CEO Omar Ishrak in 2013 with the idea that diverse perspectives and people produce better decisions, better outcomes and better business performance.

  • GlobeNewswire

    Phoenix Children’s Is the First-Ever Health System in the U.S to Use Medtronic Stealth Autoguide™ Cranial Robotic Guidance Platform for Neurosurgery

    DUBLIN and PHOENIX, Jan. 16, 2020 (GLOBE NEWSWIRE) --  Nationally ranked pediatric leader, Phoenix Children’s Hospital, is the first-ever health system in the U.S. to receive and deploy the newly FDA-cleared Medtronic Stealth Autoguide™ platform. Medtronic, a global leader in medical technology, chose Barrow Neurological Institute (BNI) at Phoenix Children’s as its first partner using this robotic technology. The highly advanced surgical tool is intended for use with the Medtronic StealthStation™ system, and Phoenix Children’s Hospital will use it in surgery for pediatric patients suffering from a range of neurological conditions.

  • GlobeNewswire

    Medtronic Receives CE Mark for InterStim™ Micro Neurostimulator and InterStim™ SureScan™ MRI Leads

    DUBLIN, Jan. 13, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) today announced it has received CE Mark for its InterStim™ Micro neurostimulator and InterStim™ SureScan™ MRI leads — clearing the technologies for commercial sale and clinical use in Europe. The availability of the new technologies on January 15 will expand access to sacral neuromodulation (SNM) therapy for thousands of potential European patients by offering full-body MRI scan eligible, lifestyle-friendly choices with either the InterStim Micro or InterStim II neurostimulators.

  • GlobeNewswire

    Medtronic Receives CE Mark Approval for the Percept™ PC Neurostimulator DBS System with BrainSense™ Technology

    DUBLIN, Jan. 09, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) today announced the CE (Conformité Européenne) Mark for Percept™ PC neurostimulator; it is the only Deep Brain Stimulation (DBS) system to be launched in the European Union (EU) with BrainSense™ technology that can sense and record brain signals while delivering therapy to patients with neurologic disorders, such as Parkinson’s disease. BrainSense technology enables physicians to track patient-specific brain signals and correlate these with patient-recorded events, such as symptoms or side-effects associated with their disease or the medications to treat it.

  • GlobeNewswire

    Medtronic Acquires Stimgenics, Pioneer of DTM™, a Novel Spinal Cord Stimulation Therapy

    Medtronic plc (MDT) announced it has acquired Stimgenics, LLC, a privately-held company based in Bloomington, Illinois, that has pioneered a novel spinal cord stimulation (SCS) waveform known as Differential Target Multiplexed (DTM™) Spinal Cord Stimulation. The therapy, which is delivered via the Medtronic Intellis™ platform, is a new and unique programming option to treat patients with chronic pain.

  • GlobeNewswire

    Medtronic Chairman and CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference

    DUBLIN, Jan. 06, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT), the global leader in medical technology, today announced it will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. Omar Ishrak, Medtronic chairman and chief executive officer, will make a formal presentation on the company beginning at 9:00 a.m. PST (11:00 a.m. CST) on Monday, January 13, 2020. In addition, the company will webcast the question and answer breakout session immediately following its presentation at 9:30 a.m. PST (11:30 a.m. CST) where Ishrak and Karen Parkhill, executive vice president and chief financial officer, will answer questions on the company.

  • GlobeNewswire

    Medtronic Expands Surgical Synergy(SM) with FDA Clearance of the Stealth Autoguide™ System for Cranial Procedures

    Robotic Trajectory Guidance Platform Integrates Multiple Enabling Technologies to Support Complex Cranial Procedures DUBLIN, Dec. 18, 2019 --  Medtronic plc (NYSE:MDT).

  • GlobeNewswire

    Medtronic Acquires Klue

    DUBLIN, Dec. 17, 2019 (GLOBE NEWSWIRE) --  Medtronic plc (MDT), the global leader in medical technology, today announced it has completed the acquisition of Klue, a software company focused on behavior tracking that can provide real-time insights into when a person is consuming food. Klue’s technology is expected to be incorporated into the Medtronic Personalized Closed Loop (PCL) insulin pump system, currently in development. The PCL system is designed to automate insulin delivery in a way that is real-time, personalized and adapts to the user, with a goal of dramatically simplifying diabetes management for the patient.

  • GlobeNewswire

    Medtronic and ChristianaCare Collaborate to Improve Patient Outcomes and Reduce Cost of Care in Delaware

    DUBLIN and NEW CASTLE, Del., Dec. 16, 2019 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) and ChristianaCare today announced a collaboration designed to improve outcomes for ChristianaCare patients in Delaware and the surrounding region. The five-year agreement will focus on developing and deploying value-based healthcare initiatives to help ChristianaCare apply the right medical technologies and therapies to patients who may benefit most, with shared financial accountability between ChristianaCare and Medtronic to improve patient outcomes while reducing the cost of care.

  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
    PR Newswire

    ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock

    ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of 47,782,500 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $149.6 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares sold in the offering were sold by ViewRay. The shares sold included the full exercise of the underwriters' option to purchase additional shares.

  • GlobeNewswire

    Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2020

    DUBLIN, Dec. 06, 2019 -- The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2020 third quarter cash dividend of $0.54 per ordinary share,.

  • ViewRay Announces Pricing of Public Offering of Common Stock
    PR Newswire

    ViewRay Announces Pricing of Public Offering of Common Stock

    ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 41,550,000 shares of common stock at a price to the public of $3.13 per share, for gross proceeds of approximately $130.1 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 6,232,500 shares of common stock at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswire

    Medtronic Drug-Coated Balloon Receives U.S. FDA Approval to Treat Arteriovenous Fistula Lesions

    Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval of the IN.PACT™ AV drug-coated balloon (DCB), a paclitaxel-coated balloon indicated for the treatment of failing arteriovenous (AV) access in patients with end-stage renal disease (ESRD) undergoing dialysis. AV fistulae are created and used to enable hemodialysis for patients with ESRD.

  • GlobeNewswire

    Medtronic Reports Second Quarter Financial Results

    Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic GAAP Diluted EPS of $1.01; Non-GAAP Diluted EPS of $1.31 Cash Flow from Operations of $1.9 Billion Grew 61%;.

  • GlobeNewswire

    Medtronic Highlights Leadership in Inclusion, Diversity, and Equity in 2019 Integrated Performance Report

    The Medtronic 2019 Integrated Performance Report Shares Progress on Pay Equity, Diversity in Management Roles, Access to Healthcare, Environmental Performance, UN Sustainable.

  • GlobeNewswire

    New Study Shows Promise in Treating More Patients with World’s Smallest Pacemaker

    DUBLIN, Nov. 11, 2019 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) today announced results from the MARVEL 2 (Micra Atrial Tracking Using A Ventricular accELerometer) study showing that an investigational set of algorithms in the Micra™ Transcatheter Pacing System (TPS) significantly improves synchrony and cardiac function in patients with impaired electrical conduction between the chambers of the heart, called atrioventricular (AV) block. The results from the MARVEL 2 study will be presented Nov. 16 during a Featured Science session at American Heart Association 2019, the AHA Scientific Sessions and were published today in JACC: Clinical Electrophysiology.

  • GlobeNewswire

    Four-Year Data from the IN.PACT Global Study Highlight Durable Performance and Safety of IN.PACT™ Admiral™ DCB

    DUBLIN and LAS VEGAS, Nov. 05, 2019 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) today announced four-year data from the IN.PACT Global study, which reinforce the long-term durability and safety of the IN.PACT™ Admiral™ drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries. Professor Thomas Zeller, M.D., director of the Department of Angiology at Universitaets-Herzzentrum, Freiburg-Bad Krozingen, Germany, presented the new, four-year results from the full clinical cohort of the IN.PACT Global Study. The results are the first four-year, real-world, fully adjudicated DCB data to be presented in a scientific congress.

  • GlobeNewswire

    Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2020

    Medtronic plc (MDT) announced today that it will report financial results for the second quarter of fiscal year 2020 on Tuesday, November 19, 2019. The news release will include summary financial information for the company’s second quarter of fiscal year 2020, which ended on Friday, October 25, 2019. Medtronic will host a webcast at 7:00 a.m. CST to discuss financial results for its second quarter of fiscal year 2020.

  • GlobeNewswire

    Medtronic Announces Shonin Approval and Launch of the Valiant Navion™ Thoracic Stent Graft System in Japan

    Medtronic plc (MDT) today announced Shonin approval from the Ministry of Health, Labour and Welfare (MHLW) and the launch of the Valiant Navion™ thoracic stent graft system in Japan for the minimally invasive repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD). The news marks the third major geographical launch of the Valiant Navion, following FDA and CE Mark approvals in late 2018. The low-profile Valiant Navion system is built to further improve upon the performance of the market-leading Valiant™ Captivia™ thoracic stent graft system, which has treated more than 100,000 patients globally, while also broadening patient applicability.

  • GlobeNewswire

    Medtronic Launches New Activa™ Patient Programmer for DBS Therapy

    Medtronic plc (MDT) today announced the U.S. launch of its advanced Patient Programmer technology for Deep Brain Stimulation (DBS) therapy at the Samsung Developers Conference in San Jose, Calif. The new programmer – which received U.S. Food and Drug Administration (FDA) approval on July 3, 2019 – leverages a user-friendly, custom-configured Samsung mobile device which allows patients to manage their therapy more simply and discreetly. To date, more than 150,000 patients have been implanted with Medtronic DBS devices for management of Parkinson’s symptoms and other conditions. “It is important for patients to have access to advanced technology for user-friendly therapy management at home,” says Sandeep Thakkar, D.O., neurologist and movement disorder specialist at Hoag’s Pickup Family Neurosciences Institute.

  • GlobeNewswire

    Medtronic Receives FDA “Breakthrough Device Designation” for Developing Fully Implantable Heart Pump

    Medtronic plc (MDT), the global leader in medical technology, today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Medtronic Fully Implantable Left Ventricular Assist Device (LVAD) for patients with advanced heart failure, currently in development. Currently, LVAD systems include an implanted heart pump to increase the amount of blood that circulates through the body. The FDA Breakthrough Device Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.

  • GlobeNewswire

    Sean Salmon Named Executive Vice President and Group President of Medtronic Diabetes

    Medtronic plc (MDT) today announced that Sean Salmon, previously Senior Vice President (SVP) and President, Coronary and Structural Heart (CSH) within the Cardiac and Vascular Group of Medtronic, has been named Executive Vice President (EVP) and Group President of Medtronic Diabetes, effective today. Salmon will serve on the company’s Executive Committee and succeeds Hooman Hakami, who is leaving Medtronic.

  • GlobeNewswire

    Medtronic Launches the First Artificial Intelligence System for Colonoscopy at United European Gastroenterology Week 2019

    Medtronic plc (MDT), the global leader in medical technology, today announced the launch of GI Genius™ intelligent endoscopy module at UEG Week in Barcelona, Spain. The GI Genius™ module is the first system worldwide using artificial intelligence to detect colorectal polyps. It provides physicians with a powerful new solution in the fight against colorectal cancer.

  • GlobeNewswire

    FDA Classifies Medtronic Sherpa Delivery Catheter Field Action Initiated in March 2019 as Class I Recall

    DUBLIN, Oct. 09, 2019 -- Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) has classified the company’s voluntary field action initiated in.

  • GlobeNewswire

    Medtronic Receives FDA Breakthrough Device Designation for Developing Stent Graft System to Treat Thoracoabdominal Aortic Aneurysm

    Medtronic plc (MDT) today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Valiant® TAAA Stent Graft System for minimally invasive repair of thoracoabdominal aortic aneurysm (TAAA). A TAAA is a complex condition causing a bulging of the aorta, which extends from the chest down into to the abdomen.